Dyne Therapeutics (Nasdaq:DYN) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

DYN Overzicht aandelen

DYN fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 66.85% per jaar groeien

Analisten zijn het erover eens dat de aandelenkoers met 52.5% zal stijgen

Risicoanalyse

Aandeelhouders zijn het afgelopen jaar substantieel verwaterd

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Volatiele aandelenkoers in de afgelopen 3 maanden

Dyne Therapeutics, Inc. Concurrenten

Apogee Therapeutics

NasdaqGM:APGE

US$3.3b

TG Therapeutics

NasdaqCM:TGTX

US$3.2b

Merus

NasdaqGM:MRUS

US$3.4b

MoonLake Immunotherapeutics

NasdaqCM:MLTX

US$3.3b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Dyne Therapeutics
Historische aandelenkoersen
Huidige aandelenkoers	US$33.55
52 Week Hoogtepunt	US$47.45
52 Week Laag	US$6.40
Bèta	1.05
11 maand verandering	5.04%
3 maanden verandering	-2.47%
1 Jaar Verandering	255.40%
33 jaar verandering	123.37%
5 jaar verandering	n/a
Verandering sinds IPO	40.38%

Recent nieuws en updates

Dyne Therapeutics: Management Merry-Go-Round, Shaky Data Rock Wall Street

Sep 04

Companies Like Dyne Therapeutics (NASDAQ:DYN) Are In A Position To Invest In Growth

Aug 14

Recent updates

Dyne Therapeutics: Management Merry-Go-Round, Shaky Data Rock Wall Street

Sep 04

Companies Like Dyne Therapeutics (NASDAQ:DYN) Are In A Position To Invest In Growth

Aug 14

We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully

Dec 10

Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Invest In Growth?

Aug 26

Dyne wins regulatory nod to start trial for myotonic dystrophy candidate

Jul 12

Dyne stock rises 12% as FDA lifts hold on starting muscle disorder study of DYNE-251

Jul 05

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

May 05

We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely

Jan 12

We Think Dyne Therapeutics (NASDAQ:DYN) Can Afford To Drive Business Growth

Sep 29

Dyne Therapeutics' chief scientific officer Romesh Subramanian steps down

Jun 02

Here's Why We're Not Too Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

May 12

Dyne Therapeutics EPS beats by $0.10

May 06

Could The Dyne Therapeutics, Inc. (NASDAQ:DYN) Ownership Structure Tell Us Something Useful?

Jan 27

Rendement voor aandeelhouders

	DYN	US Biotechs	US Markt
7D	-3.1%	-0.2%	-0.4%
1Y	255.4%	22.1%	34.1%

Rendement versus industrie: DYN overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 22.1 % opleverde.

Rendement versus markt: DYN overtrof de US markt, die het afgelopen jaar een rendement opleverde van 34.1 %.

Prijsvolatiliteit

Is DYN's price volatile compared to industry and market?
DYN volatility
DYN Average Weekly Movement	11.3%
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van DYN is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 11% ) van DYN is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2017	152	John Cox	www.dyne-tx.com

Dyne Therapeutics, Inc., een bedrijf in spierziekten in een klinische fase, is een biotechnologiebedrijf dat zich richt op het ontwikkelen van therapeutica voor genetisch bepaalde spierziekten in de Verenigde Staten. Het ontwikkelt een portefeuille van therapeutica voor spierziekten, waaronder programma's voor myotone dystrofie type 1, duchenne spierdystrofie en facioscapulohumerale dystrofie, evenals zeldzame skeletspier-, hart- en stofwisselingsspierziekten, waarbij gebruik wordt gemaakt van het FORCE-platform dat ziektemodificerende therapeutica levert. Dyne Therapeutics, Inc. werd opgericht in 2017 en het hoofdkantoor is gevestigd in Waltham, Massachusetts.

Dyne Therapeutics, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Dyne Therapeutics zich tot de beurswaarde?
DYN fundamentele statistieken
Marktkapitalisatie	US$3.57b
Inkomsten(TTM)	-US$257.60m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-13.1x

Koers/Winstverhouding

Is DYN overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
DYN resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	US$257.60m
Inkomsten	-US$257.60m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-2.57
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde DYN op de lange termijn?

Bekijk historische prestaties en vergelijking

DYN Overzicht aandelen

Beloningen

Risicoanalyse

Dyne Therapeutics, Inc. Concurrenten

NasdaqGM:APGE

US$3.3b

NasdaqCM:TGTX

US$3.2b

NasdaqGM:MRUS

US$3.4b

NasdaqCM:MLTX

US$3.3b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

CEO, President & Director recently bought US$1.1m worth of stock

Dyne Therapeutics: Management Merry-Go-Round, Shaky Data Rock Wall Street

Dyne Therapeutics, Inc Announces Management Changes

Companies Like Dyne Therapeutics (NASDAQ:DYN) Are In A Position To Invest In Growth

Price target increased by 8.9% to US$50.00

Chief Operating Officer notifies of intention to sell stock

Recent updates

CEO, President & Director recently bought US$1.1m worth of stock

Dyne Therapeutics: Management Merry-Go-Round, Shaky Data Rock Wall Street

Dyne Therapeutics, Inc Announces Management Changes

Companies Like Dyne Therapeutics (NASDAQ:DYN) Are In A Position To Invest In Growth

Price target increased by 8.9% to US$50.00

Chief Operating Officer notifies of intention to sell stock

Dyne Therapeutics, Inc. Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress

Chief Operating Officer notifies of intention to sell stock

Dyne Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $325.5 million.

New major risk - Shareholder dilution

Chief Scientific Officer notifies of intention to sell stock

Dyne Therapeutics: Progress Undenied In DM1 And DMD Trials

Dyne Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

We're Not Very Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Dyne Therapeutics, Inc., Annual General Meeting, May 22, 2024

Dyne Therapeutics, Inc. Announces Chief Executive Officer Changes

CEO, President & Director recently sold US$223k worth of stock

Chief Operating Officer recently sold US$725k worth of stock

Price target increased by 8.3% to US$37.56

Dyne: H2 2024 Muscle Disease Data Could Boost Value

Dyne Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

CEO, President & Director notifies of intention to sell stock

Chief Business Officer exercised options and sold US$476k worth of stock

New major risk - Shareholder dilution

Dyne Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $300.125 million.

Dyne Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $300.125 million.

Dyne Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $175 million.

Chief Business Officer notifies of intention to sell stock

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Chief Operating Officer notifies of intention to sell stock

New major risk - Financial position

CEO, President & Director notifies of intention to sell stock

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

New major risk - Financial position

Insufficient new directors

CEO, President & Director recently sold US$618k worth of stock

CEO, President & Director notifies of intention to sell stock

Dyne Therapeutics, Inc. Announces Resignation of Dr. Lawrence Klein as Board Member

Insufficient new directors

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Price target increased by 9.6% to US$28.50

Insider exercised options and sold US$133k worth of stock

Insider notifies of intention to sell stock

We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully

Dyne Therapeutics, Inc. Receives Fda Fast Track Designation for Dyne-251 for the Treatment of Duchenne Muscular Dystrophy

CEO, President & Director exercised options and sold US$2.4m worth of stock

Dyne Therapeutics, Inc. Presents Preclinical Data from Its Duchenne Muscular Dystrophy Programs Targeting Exons 51 and 53 At World Muscle Society 2022 Congress

Dyne Therapeutics, Inc. Prioritizes its Focus and Resources on its Clinical Programs, DYNE-101 in DM1 and DYNE-251 in DMD

Dyne Therapeutics Announces Initiation of Phase 1/2 ACHIEVE Clinical Trial of DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

Dyne Therapeutics, Inc. Appoints Francesco Bibbiani as Senior Vice President, Head of Development

Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Invest In Growth?

Dyne Therapeutics, Inc. Announces “Breakthrough Article” Publication of Duchenne Muscular Dystrophy Program Data in Nucleic Acids Research

High number of new directors

Price target decreased to US$24.67

Dyne Therapeutics Announces Clearance of Clinical Trial Application for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

Dyne wins regulatory nod to start trial for myotonic dystrophy candidate

Dyne Therapeutics, Inc. Announces FDA Clearance of IND Application for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy

Dyne stock rises 12% as FDA lifts hold on starting muscle disorder study of DYNE-251

Dyne Therapeutics, Inc. Presents New In Vivo Data from DYNE-101